PROCEPT BioRobotics (NASDAQ:PRCT) Posts Quarterly Earnings Results, Beats Expectations By $0.04 EPS

PROCEPT BioRobotics (NASDAQ:PRCT) announced its quarterly earnings results on Wednesday. The company reported ($0.51) EPS for the quarter, beating the consensus estimate of ($0.55) by $0.04, Briefing.com reports. The business had revenue of $44.50 million during the quarter, compared to analysts’ expectations of $41.58 million. PROCEPT BioRobotics had a negative return on equity of 42.13% and a negative net margin of 66.12%. The firm’s quarterly revenue was up 82.4% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($0.63) EPS. PROCEPT BioRobotics updated its FY 2024 guidance to EPS.

PROCEPT BioRobotics Stock Performance

PRCT stock traded up $2.57 during mid-day trading on Friday, reaching $64.31. 1,143,117 shares of the stock traded hands, compared to its average volume of 664,889. The business has a 50-day moving average of $50.25 and a two-hundred day moving average of $43.61. PROCEPT BioRobotics has a 52 week low of $24.83 and a 52 week high of $64.89. The company has a quick ratio of 6.77, a current ratio of 7.63 and a debt-to-equity ratio of 0.18.

Insider Transactions at PROCEPT BioRobotics

In other news, EVP Alaleh Nouri sold 5,306 shares of PROCEPT BioRobotics stock in a transaction that occurred on Wednesday, February 7th. The stock was sold at an average price of $49.95, for a total transaction of $265,034.70. Following the sale, the executive vice president now owns 47,351 shares of the company’s stock, valued at approximately $2,365,182.45. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In related news, CEO Reza Zadno sold 5,391 shares of the business’s stock in a transaction on Monday, March 18th. The stock was sold at an average price of $48.83, for a total value of $263,242.53. Following the sale, the chief executive officer now owns 241,319 shares of the company’s stock, valued at approximately $11,783,606.77. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, EVP Alaleh Nouri sold 5,306 shares of the business’s stock in a transaction dated Wednesday, February 7th. The shares were sold at an average price of $49.95, for a total transaction of $265,034.70. Following the completion of the transaction, the executive vice president now owns 47,351 shares in the company, valued at $2,365,182.45. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 124,581 shares of company stock worth $6,570,023. Company insiders own 19.60% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts recently issued reports on the stock. Wells Fargo & Company upped their price objective on shares of PROCEPT BioRobotics from $44.00 to $47.00 and gave the stock an “overweight” rating in a report on Tuesday, January 9th. Truist Financial boosted their price target on PROCEPT BioRobotics from $63.00 to $72.00 and gave the stock a “buy” rating in a research report on Thursday. Six equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average price target of $49.50.

About PROCEPT BioRobotics

PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH).